8 Multiple Sclerosis Flashcards

1
Q

MS Etiology

A

2.3 million people worldwide
Women 2-3x more likely than men
Most commonly diagnosed 25-35 y/o
Strong correlation between MS prevalence and distance from equator- vit D may be a factor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Factors that may cause MS

A

Lower risk closer to equator
Smoking increases risk
Higher risk if parent or sibling has it
Human herpes virus-6, Epstein-Barr, chlamydia pneumoniae bacteria, canine distemper, measles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Pathology of MS

A

Acute demyelination of axons- recovery with axonal plasticity/re-myelination early on, but permanent axonal damage later on

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

McDonald criteria overview

A

Dissemination in time- 2 or more distinct attacks
Dissemination in space- 2 or more lesions in CNS
Exclusion of other diagnoses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

McDonald criteria for diagnosis

A

2 attacks + 2 lesions = no additional info needed
2 attacks + 1 lesion = need diss in space
1 attack + 2 lesions = need diss in time
1 attack + 1 lesion = need both
Progressive course over 1 year- need diss in space by two of: MRI brain, MRI SC, CSF fluid oligoclonal bands

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

MRI types

A

T1- detects active inflammation
T2- detects old and new lesions
FLAIR (fluid attenuated inversion recovery)- subtle changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Evoked potentials

A

Sensory- impulses to arm or leg
Brainstem auditory- listen for series of clicks in each ear
Visual- observe alternating checkerboard pattern, identifies pathologic transmission along optic nerve pathway, only type proven useful in MS diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

CSF analysis

A

Obtained via lumbar puncture
Findings- IgG, oligoclonal bands, certain proteins common with myelin breakdown (immune-related markers)
Not specific to MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Sensory and pain symptoms

A

Paresthesias (most commonly begin distally)
Loss of proprioception and vibratory sense
Dyesthetic pain (pain not provoked by stimulus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Visual symptoms

A

Optic neuritis- blurred vision, change in color perception, visual field deficit = most common
Nystagmus
Oscillopsia
Intranuclear opthalmaplegia (disconjucate eye movements)
Optic disc pallor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Heat intolerance symptoms

A

Sensitivity to changes in core body temperature
Uhthoff phenomenon- increase in body temp causes increased in neurologic symptoms
Neuroblockade hypothesis- increased temp decreases nerve conduction in partially demyelinated fibers (greater demyelination –> greater conduction loss)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Primary MS fatigue

A

Central fatigue- demyelination leads to failure of motor pathways during rapid activity
Decreased efficiency of motor unit activation- dec oxidative capacity, slow muscle contractile properties, decrease number of slow-twitch fibers, lower tetanic and twitch tension in muscles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Cerebellar symptoms

A

Ataxia, incoordination, dizziness, imbalance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Urinary symptoms

A

Incontinence, incomplete emptying, increased frequency

Can get UTIs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cognitive symptoms

A

Emotional lability, depression, anxiety, decreased executive functioning

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Krutzke expanded disability status scale (EDSS)

A

0 (no disability) to 10 (death)
0-4.5 can walk independently
5.0-9.5 impairments in ambulation

Functional systems- pyramidal (motor function), cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral or mental, other
FS scored 0 (low level of problems) to 5 (high level)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

EDSS cutoffs

A
  1. 0- minimal disability in one FS (one S grade 2, others 0 or 1)
  2. 0- ambulates without aid or rest 200 m, disability severe enough to impair ADLs
  3. 0- essentially restricted to bed or chair but may be out of bed much of day. Retains many self-care functions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Relapsing-remitting

A

Most common 80%

Temp relapses lasting 1-3 months, complete or partial recovery between

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Secondary-progressive

A

Second phase of RRMS if not treated

Progressive worsening, may or may not have relapses and remissions

20
Q

Primary progressive

A

Steady worsening, no relapses or remissions

21
Q

Progressive-relapsing

A

Steady worsening with intermittent acute flare-ups

22
Q

Malignant MS

A

Rapid and progressive

23
Q

Prognostic factors

A

Positive- RRMS, one symptom at onset

Negative- PPMS, older age at onset, male, African-American, early cerebellar or pyramidal signs, smoking, low vit D

24
Q

Relapse/exacerbation management meds

A

Corticosteroids- IV or oral, high dose, short duration

25
Function of disease-modifying meds
Reduce number and severity of relapses Reduce development of new areas of inflammation Delay disability progression Most act as immune-system modulators
26
Injectable disease-modifying meds
Avonex (interferon beta-1a) Betaseron (interferon beta-1b) Copaxone (glatiramer acetate) Rebif (interferon beta-1a)
27
Oral disease-modifying meds
Aubagio (teriflunomide) Gilenya (finfolimod) Tecfidera (dimethyl fumarate)
28
Infused disease-modifying meds
Novantrone (mitoxantrone) Tysabri (natalizumab) Lemtrada (aletuzumab)
29
Exercise effects for MS
No decrease in pro-inflammatory or anti-inflammatory markers No increase in neurotrophic factors Correlation high aerobic capacity and structure preservation No worsening, possible improvement in fatigue Significant improvement in depressive symptoms and QOL Trend to improved cognition Improved muscle strength Improvement in aerobic capacity Gait speed and endurance improvements Self-perceived ability to do ADLs trend for improvement
30
Gait training results
Increase in swing time, step length, stride length, foot angle Decrease in time in stance and DL support and toe clearance Improved isometric strength, disability score, 3-minute stepping
31
Treadmill training results
30 min 3x/week at 55-85% max HR Significant increase in gait speed Trend to improved endurance and fatigue levels Faster rate of detraining
32
Results of aquatic therapy
Improved QOL/ decreased fatigue Improved gait speed, BBS, TUG, grip strength Decreased neuromuscular deficits
33
Fatigue impact
No significant difference in EDSS scores between low and high fatigue groups Higher levels of fatigue reported = greater impairments in functional mobility, depression, physical and mental QOL Disability not related to level of fatigue
34
Effects of exercise on fatigue
No significant change in fatigue after exercise No significant change in functional ability after exercise Increased symptoms may happen after exercise, but temporary and unlikely to have deleterious effects on fatigue and function
35
Exercise parameters to reduce fatigue
Endurance, resistance, and combined training | 2-3 days/week, 60-80% max HR, 30 minutes/day
36
Acute care EDGE highly recommended measures
``` 12-item MS walking scale 9-hole peg test BBS MS impact scale (MSIS-29) Timed 25-foot walk TUG cognitive and manual ```
37
12-item MS walking scale
Questionnaire to measure ability to ambulate 12-60 points (higher number = greater disability) No cut-offs
38
9-hole peg test
Measures finger dexterity- time to place all pegs in holes and return to container No cut-offs, but norms for different populations
39
MS impact scale (MSIS-29)
Questionnaire measuring physical and psychological impact of MS on daily life 1 (no impact)- to 5 (extreme impact) No cut-offs
40
Timed 25-foot walk
Quantitative measure of mobility and leg strength Average 2 timed trials No cut-offs
41
TUG cognitive and manual
Cog- backwards by threes Man- hold cup of water Manual- 14.5 seconds or longer, difference of 4.5 seconds between manual and TUG Cognitive- 15 seconds or longer
42
Inpatient and outpatient rehab EDGE highly recommended
``` 12-item MS walking scale 6MWT 9-hole peg test BBS DHI MS functional composite MS impact scale MS quality of life Timed 25 foot walk TUG cognitive and manual ```
43
Dizziness handicap inventory
0-100 (higher score is greater handicap) | >59 risk for falls in MS
44
MS functional composite
Evaluates cognition, gait, and UE function in individuals with MS Includes timed 25-foot walk, 9-hole peg test, paced auditory serial addition test Convert to z-score, averaged
45
MS quality of life (MS QOL-54)
Focuses on physical health and mental health for MS No overall score, but summary for physical and mental health weighted based on combo of scale scores Each question is Likert scale